| Title |
Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging
|
|---|---|
| Published in |
Annals of Surgical Oncology, April 2018
|
| DOI | 10.1245/s10434-018-6453-2 |
| Pubmed ID | |
| Authors |
Willemieke S. Tummers, Sarah E. Miller, Nutte T. Teraphongphom, Adam Gomez, Idan Steinberg, David M. Huland, Steve Hong, Sri-Rajasekhar Kothapalli, Alifia Hasan, Robert Ertsey, Bert A. Bonsing, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg, Teri A. Longacre, George A. Fisher, Sanjiv S. Gambhir, George A. Poultsides, Eben L. Rosenthal |
| Abstract |
Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor. A dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo. Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue. The safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated. |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 18% |
| Mexico | 4 | 18% |
| Italy | 1 | 5% |
| Poland | 1 | 5% |
| Spain | 1 | 5% |
| Norway | 1 | 5% |
| Sweden | 1 | 5% |
| Brazil | 1 | 5% |
| Unknown | 8 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 64% |
| Scientists | 5 | 23% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 21% |
| Student > Master | 15 | 18% |
| Student > Doctoral Student | 8 | 10% |
| Researcher | 7 | 9% |
| Student > Bachelor | 6 | 7% |
| Other | 9 | 11% |
| Unknown | 20 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 26% |
| Engineering | 10 | 12% |
| Biochemistry, Genetics and Molecular Biology | 9 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 11 | 13% |
| Unknown | 22 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2018.
All research outputs
#2,927,436
of 23,313,051 outputs
Outputs from Annals of Surgical Oncology
#802
of 6,609 outputs
Outputs of similar age
#61,764
of 327,765 outputs
Outputs of similar age from Annals of Surgical Oncology
#19
of 100 outputs
Altmetric has tracked 23,313,051 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,609 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,765 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.